Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Supination

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

  • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).


    The EU Clinical Trials Register currently displays   43881   clinical trials with a EudraCT protocol, of which   7295   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    5 result(s) found for: Supination. Displaying page 1 of 1.
    EudraCT Number: 2006-002175-40 Sponsor Protocol Number: no number Start Date*: 2008-12-17
    Sponsor Name:
    Full Title: Effect of Botulinum Toxin A Injections and Specific Intensive Rehabilitation Therapy in Children with Hemiparetic Cerebral Palsy on Upper Limb Functions and Skills
    Medical condition: Study design: a factorial design with four study groups in which btA alone, intensive rehabilitation therapy aimed at improving bimanual skills alone, a combination of these two and continuing the ...
    Disease:
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2005-002088-98 Sponsor Protocol Number: AN01.01.0012 Start Date*: 2005-11-07
    Sponsor Name:Amarin Neuroscience Ltd
    Full Title: Full title of the trial : A multicentre, multi-national, double-blind, randomised, parallel group placebo-controlled trial of ethyl-EPA (ethyl-icosapent) in patients with Huntington’s Disease
    Medical condition: HUNTINGTON’S DISEASE
    Disease: Version SOC Term Classification Code Term Level
    8.0 10010331 LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended) ES (Ongoing) AT (Prematurely Ended) IT (Prematurely Ended) PT (Prematurely Ended) DE (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2013-002899-41 Sponsor Protocol Number: 8-55-52966-005 Start Date*: 2014-04-28
    Sponsor Name:Ipsen Pharma
    Full Title: A dose escalation, proof of concept, phase IIa study to investigate the safety and tolerability, the pharmacokinetic and the pharmacodynamic of BN82451B, administered twice daily over 4 weeks, in ...
    Medical condition: Huntington's disease
    Disease: Version SOC Term Classification Code Term Level
    18.1 10010331 - Congenital, familial and genetic disorders 10070668 Huntington's disease PT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: DE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2015-000373-13 Sponsor Protocol Number: AMBS-ELTO-201 Start Date*: 2015-08-18
    Sponsor Name:Amarantus BioScience Holdings, Inc.
    Full Title: Phase 2, multicenter, randomized, double-blind, placebo-controlled, four-period cross-over, dose-range finding study to evaluate the safety, tolerability and efficacy of Eltoprazine in the treatmen...
    Medical condition: Parkinson’s disease levodopa induced dyskinesia (PD-LID)
    Disease: Version SOC Term Classification Code Term Level
    18.0 10029205 - Nervous system disorders 10061536 Parkinson's disease PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Temporarily Halted)
    Trial results: (No results available)
    EudraCT Number: 2020-002822-10 Sponsor Protocol Number: PL101-HD301 Start Date*: 2020-12-11
    Sponsor Name:Prilenia Neurotherapeutics Ltd.
    Full Title: A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel Arm, Multicenter Study Evaluating the Efficacy and Safety of Pridopidine in Patients with Early Stage of Huntington Disease
    Medical condition: Huntington Disease
    Disease: Version SOC Term Classification Code Term Level
    20.0 10010331 - Congenital, familial and genetic disorders 10070668 Huntington's disease PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Ongoing) AT (Ongoing) FR (Ongoing) CZ (Ongoing) NL (Ongoing) IT (Ongoing)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sun May 19 19:56:34 CEST 2024 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA